One of the extensively explored targets to develop COVID-19 specific drug(s) (Shah et al., 2022) is an interaction between the receptor-binding domain (RBD) of the virus’ spike (S) glycoprotein (Wrapp et al., 2020) and human receptor angiotensin-converting enzyme 2 (ACE2) (Walls et al., 2020). The gene discussed is ACE2; the disease is COVID-19.